Urinary Biomarkers for Radiation Cystitis: Current Insights and Future Directions
International Journal of Molecular Sciences · 06.01.2026 · 27 (2) · 565
DOI: 10.3390/ijms27020565 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.01.2026. Verfasst von Rani Mahyoob und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48073, USA. Hauptthemen laut MEDLINE: Biomarkers, Cystitis, Radiation Injuries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, The National Institute of Diabetes and Digestive and Kidney Diseases, NIH., the National Institute of Diabetes and Digestive and Kidney Diseases, NIH.
Abstract (Originalsprache)
Radiation cystitis (RC) is a clinically challenging and often progressive complication of pelvic radiotherapy, marked by urothelial injury, vascular dysfunction, chronic inflammation, and fibrotic remodeling. Early diagnosis remains elusive due to nonspecific symptoms and the absence of validated molecular tools. As a biofluid in direct contact with the irradiated bladder, urine offers a unique molecular window into RC pathogenesis. In this review, we synthesize the current landscape of urinary biomarkers associated with the acute, latent, and chronic phases of RC, including inflammatory cytokines, oxidative stress products, epithelial injury markers, extracellular vesicles, microRNAs, proteomic signatures, and metabolomic alterations. We also integrate emerging mechanistic insights such as DNA damage responses, ROS generation, mitochondrial dysfunction, urothelial barrier disruption, senescence-associated secretory phenotypes, hypoxia-driven vascular injury, and profibrotic TGF-β signaling, all of which contribute to the release of urinary analytes. By linking phase-specific molecular pathways with corresponding urinary signatures, we highlight opportunities to leverage urine-based measurements for early detection, risk stratification, severity assessment, and therapeutic monitoring. A deeper understanding of the molecular mechanisms shaping urinary biomarker profiles will be essential for advancing precision diagnostics and improving long-term outcomes for patients with radiation cystitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48073, USA.
- Department of Urology, William Beaumont School of Medicine, Oakland University, Rochester, MI 48073, USA.
Förderung
- NIDDK NIH HHS
- The National Institute of Diabetes and Digestive and Kidney Diseases, NIH.
- the National Institute of Diabetes and Digestive and Kidney Diseases, NIH
Zitieren
APA
Mahyoob, R., & Zwaans, B. M. M. (2026). Urinary Biomarkers for Radiation Cystitis: Current Insights and Future Directions. International Journal of Molecular Sciences, 27(2), 565. https://doi.org/10.3390/ijms27020565
Vancouver
Mahyoob R, Zwaans BMM. Urinary Biomarkers for Radiation Cystitis: Current Insights and Future Directions. International Journal of Molecular Sciences. 2026;27(2):565. doi:10.3390/ijms27020565
BibTeX
@article{Mahyoob2026,
author = {Mahyoob, Rani and Zwaans, Bernadette M M},
title = {Urinary Biomarkers for Radiation Cystitis: Current Insights and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {565},
doi = {10.3390/ijms27020565}
}
EUVIMED